13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001848809
Total reported value
$164.2M
$164.2M
18 檔
51.4%
During the Q3 2024 filing period, Velan Capital Investment Management LP (CIK: 0001848809) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $164.2M across 18 reported positions.
Velan Capital Investment Management LP executed strategic sector rebalancing during Q3 2024, establishing 6 new positions while fully exiting 5 holdings and trimming 3 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | JSPR | Jasper Therapeutics Inc | Stock-Other | 25.22% | -0.78% | -2.59% | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 18.87% | -2.24% | — | |
| 3 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 13.86% | — | — | |
| 4 | HRTX | Heron Therapeutics Inc | Stock-Other | 13.00% | -2.11% | — | |
| 5 | TRML | Tourmaline Bio Inc | Stock-Other | 7.96% | — | +3.80% | |
| 6 | RZLT | Rezolute Inc | Stock-Other | 3.63% | +0.95% | — | |
| 7 | LQDA | Liquidia CORP | Stock-Other | 2.81% | — | — | |
| 8 | CNTX | Context Therapeutics Inc | Stock-Other | 2.36% | -0.14% | — | |
| 9 | NSPR | Inspiremd Inc | Stock-Other | 2.27% | -2.08% | — | |
| 10 | SCPH | Scpharmaceuticals Inc | Stock-Other | 2.21% | — | — | |
| 11 | TELA | Tela Bio Inc | Stock-Other | 1.77% | — | +0.18% | |
| 12 | ✓ | Optinose Inc | Stock-Other | 1.34% | — | -13.89% | |
| 13 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 1.30% | — | — | |
| 14 | TARA | Protara Therapeutic Inc | Stock-Other | 0.98% | -2.63% | +19.58% | |
| 15 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.96% | — | — | |
| 16 | SKYE | Skye Bioscience Inc | Stock-Other | 0.77% | — | -50.00% | |
| 17 | KPRX | Kiora Pharmaceuticals Inc | Stock-Other | 0.42% | — | — | |
| 18 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.27% | -0.36% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | +13.9% | NEW | New buy |
| 2 | PRAX | Praxis Precision Medicines I | +10.6% | — | Unchanged |
| 3 | JSPR | Jasper Therapeutics Inc | +6.6% | -2.59% | Trim |
| 4 | TRML | Tourmaline Bio Inc | +5.6% | +3.80% | Add |
| 5 | LQDA | Liquidia CORP | +2.8% | NEW | New buy |
| 6 | SCPH | Scpharmaceuticals Inc | +2.2% | NEW | New buy |
| 7 | RZLT | Rezolute Inc | +1.7% | — | Unchanged |
| 8 | ZVRA | Zevra Therapeutics Inc | +1.3% | NEW | New buy |
| 9 | NSPR | Inspiremd Inc | +1% | — | Unchanged |
| 10 | CRBP | Corbus Pharmaceuticals Holdi | +1% | NEW | New buy |
| 11 | CNTX | Context Therapeutics Inc | +0.9% | — | Unchanged |
| 12 | TARA | Protara Therapeutic Inc | +0.4% | +19.58% | Add |
| 13 | TENX | Tenax Therapeutics Inc | +0.3% | NEW | New buy |
| 14 | KPRX | Kiora Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 15 | ✓ | Aslan Pharmaceuticals LTD | -0.1% | EXIT | Sold out |
| 16 | ✓ | Optinose Inc | -0.2% | -13.89% | Trim |
| 17 | ASNSUSD | X4 Pharmaceuticals Inc | -0.2% | EXIT | Sold out |
| 18 | TELA | Tela Bio Inc | -0.2% | +0.18% | Add |
| 19 | ✓ | Elevation Oncology Inc | -0.9% | EXIT | Sold out |
| 20 | HRTX | Heron Therapeutics Inc | -1% | — | Unchanged |
| 21 | OTLK | Outlook Therapeutics Inc | -1% | EXIT | Sold out |
| 22 | SKYE | Skye Bioscience Inc | -1.2% | -50.00% | Trim |
| 23 | ✓ | Alimera Sciences Inc | -43.4% | EXIT | Sold out |
According to official SEC Form 13F filings, Velan Capital Investment Management LP reported a total U.S. public equity portfolio value of $164.2M across 18 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including JSPR, PRAX, XBI) accounted for 51.4% of total reported equity market value during Q3 2024.
Top New Position Initiated
XBI
市值: $14.8M
Top Position Liquidated / Trimmed
ALIMERA SCIENCES INC
前期市值: $75.7M
During Q3 2024, Velan Capital Investment Management LP's top holdings by market value included JSPR (25.2%)、PRAX (18.9%)、XBI (13.9%). The largest single position, JSPR, represented 25.2% of total portfolio value.
In Q3 2024, Velan Capital Investment Management LP made 17 total portfolio adjustments, initiating 6 new buys, adding to 3 positions, trimming 3 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.